Abstract | PURPOSE: METHODS: A total of 142 patients with BPH-who were to undergo TURP-were enrolled and randomized into two groups. The dutasteride group comprising of 71 patients, was treated with dutasteride (0.5 mg/day) for 6 weeks before surgery and the control group, comprising of other 71 patients, did not receive dutasteride. Blood loss was evaluated in terms of a reduction in the serum hemoglobin level (ΔHb and ΔHCT), and was estimated by measuring the Hb and hematocrit levels before and 24 hours after surgery. RESULTS: None of the patients treated with dutasteride reported any side effects. A significantly lower mean blood loss was observed in the dutasteride group compared to the control group (ΔHb=-1.29 ± 0.81 v -1.83 ± 1.25, respectively, p<0.0027; ΔHCT=-5.67 ± 2.58 v -6.50 ± 2.40, respectively, p<0.0491). CONCLUSIONS: Our results showed that pretreatment with dutasteride for 6 weeks before TURP reduces the surgical bleeding considerably. This treatment schedule can be used routinely to decrease TURP surgical bleeding.
|
Authors | Antonio Luigi Pastore, Simone Mariani, Francesco Barrese, Giovanni Palleschi, Armando Manuel Valentini, Luca Pacini, Vincenzo Petrozza, Antonio Carbone, Manlio Cappa |
Journal | Journal of endourology
(J Endourol)
Vol. 27
Issue 1
Pg. 68-70
(Jan 2013)
ISSN: 1557-900X [Electronic] United States |
PMID | 23030716
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- 5-alpha Reductase Inhibitors
- Azasteroids
- Dutasteride
|
Topics |
- 5-alpha Reductase Inhibitors
(administration & dosage)
- Adult
- Aged
- Azasteroids
(administration & dosage)
- Blood Loss, Surgical
(prevention & control)
- Dose-Response Relationship, Drug
- Dutasteride
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Prostatic Hyperplasia
(drug therapy, surgery)
- Transurethral Resection of Prostate
(methods)
- Treatment Outcome
|